Literature DB >> 11391158

Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells.

G A Funk1, M Fischer, B Joos, M Opravil, H F Günthard, B Ledergerber, S Bonhoeffer.   

Abstract

Based on a mathematical model, we analyze the dynamics of CD4+ cells, actively, latently, persistently, and defectively infected cells and plasma virus after initiation of antiretroviral therapy in 14 HIV-1-infected asymptomatic patients. By simultaneous fitting of our model to clinical data of plasma HIV-1 RNA, peripheral blood mononuclear cell (PBMC)-gag RNA, proviral DNA, and CD4+ cell counts, we estimate kinetic parameters to determine the basic reproductive rate (R0) of the virus in different infected cell compartments as a measure of the replicative capacity of the virus in vivo. We find that the basic reproductive rate is larger than 1 before treatment only in actively infected cells (mean R0(act) approximately 2.46) indicating that only in this compartment the virus can maintain an ongoing infection. In latently and persistently infected cells the basic reproductive rate is considerably smaller (R0(lat) approximately 0.03 and R0(pers) approximately 0.008, respectively) indicating that these compartments contribute little to the total basic reproductive rate and cannot maintain an ongoing infection in absence of actively infected cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391158     DOI: 10.1097/00126334-200104150-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  18 in total

1.  Costs versus benefits: best possible and best practical treatment regimens for HIV.

Authors:  O Krakovska; L M Wahl
Journal:  J Math Biol       Date:  2007-01-05       Impact factor: 2.259

2.  A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.

Authors:  Philippe Jacqmin; Lynn McFadyen; Janet R Wade
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

3.  Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling.

Authors:  Philippe Jacqmin; Lynn McFadyen; Janet R Wade
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-03-04       Impact factor: 2.745

4.  Maximum likelihood estimation of long-term HIV dynamic models and antiviral response.

Authors:  Marc Lavielle; Adeline Samson; Ana Karina Fermin; France Mentré
Journal:  Biometrics       Date:  2011-03       Impact factor: 2.571

5.  From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.

Authors:  Jing Fang; Pravin R Jadhav
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-06-27       Impact factor: 2.745

6.  Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.

Authors:  Daniel Röshammar; Ulrika S H Simonsson; Håkan Ekvall; Leo Flamholc; Vidar Ormaasen; Jan Vesterbacka; Eva Wallmark; Michael Ashton; Magnus Gisslén
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-02       Impact factor: 2.745

7.  Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.

Authors:  Kun Wang; David Z D'Argenio; Edward P Acosta; Anandi N Sheth; Cecile Delille; Jeffrey L Lennox; Corenna Kerstner-Wood; Ighovwerha Ofotokun
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

8.  The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.

Authors:  Phylinda L S Chan; Philippe Jacqmin; Marc Lavielle; Lynn McFadyen; Barry Weatherley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-19       Impact factor: 2.745

9.  ESTROGEN REPLACEMENT THERAPY FOR STROKE.

Authors:  Mibel Pabon; Cyrus Tamboli; Sarosh Tamboli; Sandra Acosta; Ike De La Pena; Paul R Sanberg; Naoki Tajiri; Yuji Kaneko; Cesar V Borlongan
Journal:  Cell Med       Date:  2014-04-10

10.  Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling.

Authors:  Romulus Breban; Sonia Napravnik; James Kahn; Sally Blower
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.